{"page_content": "In line with our strategy to access cutting-edge technol-\nogy, we have a range of research collaborations providing us with access to novel peptide libraries or new technolo-gies for peptide stabilization and delivery.\nBecause of their unique features, specificity, physical \nsize and attractive risk profile, peptide-based medicines may allow us to in the future treat diseases that we can\u2019t treat today. Furthermore, they may enable us to treat more patients, initiate treatment earlier and ensure better treatment compliance, all of which could improve health outcomes.16\nZealand Pharma  \u221e  Annual Report 2021", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 15, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}